About OSE Immunotherapeutics
OSE Immunotherapeutics is a publicly listed company based in Nantes (France) founded in 1986. It operates as an immunotherapies for oncology and autoimmune diseases are developed. The company has 64 employees. OSE Immunotherapeutics offers products and services including Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument. Its focus areas include Life Sciences, Transplant Medicine, Drugs and Immunotherapy. Its competitors include Biogen, CareDx, ADMA Biologics, Kymeratx and BioNTech and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Founded in 1986 in Nantes, France, the company operates in the biotechnology sector, focusing on immunotherapies for immuno-oncology and autoimmune conditions. Key developments include the Tedopi vaccine targeting lung, ovarian, and pancreatic cancers, alongside the CoVepiT vaccine for COVID-19, OSE-172 and CLEC-1 for various cancers, a bispecific fusion protein platform, OSE-127 for ulcerative colitis and Sjogrens syndrome, FR104 for autoimmune diseases and transplantation, and OSE-230 for inflammation.
- Headquarters Nantes, France
- Employees 64
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ose-immuno.com
- Social LinkedIn X
- Legal Name Ose Immunotherapeutics Sa
- Annual Revenue$3.08 M (USD)-96.25as on Dec 31, 2025
- Net Profit-$44.29 M (USD)-200.65as on Dec 31, 2025
- EBITDA-$52.65 M (USD)-258.02as on Dec 31, 2025
- Latest Funding Round$9.12M (USD), Grant
Apr 2024
- Investors
- Employee Count64
Products & Services of OSE Immunotherapeutics
OSE Immunotherapeutics offers a comprehensive portfolio of products and services, including Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument.
Immunotherapy for activating T cells in cancer treatment.
Targets tumor microenvironment for oncology applications.
Regulates immune responses in inflammation disorders.
Modulates T cell activity for therapeutic use.
Funding Insights of OSE Immunotherapeutics
- Total Rounds 3
- Last Round Grant — $9.12M
- First Round $2.9M
(Jun 2017)
- Investors Count 1
All 3 funding rounds of OSE Immunotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in OSE Immunotherapeutics
OSE Immunotherapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France |
Investor details for OSE Immunotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of OSE Immunotherapeutics
OSE Immunotherapeutics is a publicly listed company on the EURONEXT with ticker symbol OSE in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Mar 2015
- Listed onEuronext: OSE
- Listed entityOSE Immunotherapeutics SA
- Exchange sectorHealth technology
- ISINFR0012127173
- Share price2.02 EUR (-1.37% on the day) · 2026-10-14
- Market capitalisation48,091,393.00 EUR
- Volume (last session)10,598
Financials of OSE Immunotherapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.6M EUR | -37.7M EUR | -44.8M EUR |
| 2024 | 69.9M EUR | 37.5M EUR | 28.4M EUR |
| 2023 | 2.2M EUR | -23.0M EUR | -28.9M EUR |
| 2022 | 18.3M EUR | -17.8M EUR | -20.5M EUR |
| 2021 | 26.3M EUR | -16.9M EUR | -19.4M EUR |
Detailed financial statements for OSE Immunotherapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of OSE Immunotherapeutics
4 dated milestones of OSE Immunotherapeutics across 38 years, from founding to its latest funding, stage changes and deals.
- Founded OSE Immunotherapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.9M.
- Funding Latest funding round, Grant, of $9.1M.
Competitors of OSE Immunotherapeutics
OSE Immunotherapeutics has 10 listed competitors in our database, 9 of them funded. They include Biogen, CareDx, ADMA Biologics, Kymeratx and BioNTech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| caredx.com | 1998 | Brisbane, United States | $138.21M | 645 | Medical solutions for transplant patients are developed and provided. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| biontech.com | 2008 | Mainz, Germany | $805.99M | 4,530 | Immunotherapeutics for cancer and other diseases are developed. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| ucb.com | 1928 | Brussels, Belgium | – | 79 | Therapies for immunological and neurological disorders are developed. | |
| zymeworks.com | 2003 | Vancouver, Canada | $145.97M | 277 | Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment. | |
| veratx.com | 2016 | San Francisco, United States | $196.58M | 46 | Therapeutic solutions for immunological and inflammatory diseases are developed. |
Detailed competitors of OSE Immunotherapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OSE Immunotherapeutics
The website of OSE Immunotherapeutics (ose-immuno.com) receives about 5K visits a month and ranks #2,400,237 among all websites worldwide, #3,287 in Biotechnology and Pharmaceuticals.
- Monthly visits5K
▼ 31.5% vs previous month
- Unique visitors3.5K
per month
- Global rank#2,400,237
among all websites
- Category rank#3,287
Health · Biotechnology and Pharmaceuticals
- Bounce rate28%
- Pages per visit2.9
- Average visit2 min 22 sec
- DevicesDesktop 58% · Mobile 42%
Websites whose visitors overlap most with OSE Immunotherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| clinicaltrialsarena.com | 100% | – | #257,942 | View details |
Top companies in Transplant Medicine
10 companies that operate in the same segment as OSE Immunotherapeutics (Transplant Medicine), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical solutions for transplant patients are developed and provided. | 1998 | Brisbane, California, United States | USD 138.21 M | USD 379.81 M | 650 | |
Developer of organ transplantation technology | 1998 | Andover, Massachusetts, United States | USD 265.55 M | USD 605.49 M | 728 | |
Warm storage and transport systems for harvested organs are provided. | 2008 | Oxford, Oxfordshire, United Kingdom | USD 45.42 M | USD 1.36 M | 14 | |
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 | |
Next-generation medicines for CNS and immunological disorders are developed. | 2007 | New York, New York, United States | USD 4.45 M | USD 13.11 M | 81 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Personalized skin tissue therapy is developed by CUTISS for surgeries. | 2017 | Zurich, Switzerland | USD 94.37 M | – | – | |
Game currency trading services are provided by Magenta Piman. | 2016 | Cambridge, Massachusetts, United States | USD 150.5 M | – | 75 | |
T regulatory cell therapies are developed for immunological diseases. | 2019 | London, England, United Kingdom | USD 344.25 M | – | – | |
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. | 2004 | Irvine, California, United States | USD 1.89 M | – | 31 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ose Immunotherapeutics
Complete news archive for OSE Immunotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OSE Immunotherapeutics
OSE Immunotherapeutics was founded in 1986 and raised its 1st funding round 31 years after it was founded.
OSE Immunotherapeutics is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
OSE Immunotherapeutics has 64 employees.
Annual revenue of OSE Immunotherapeutics is $3.08M as on Dec 31, 2025.
Founded in 1986 in Nantes, France, the company operates in the biotechnology sector, focusing on immunotherapies for immuno-oncology and autoimmune conditions. Key developments include the Tedopi vaccine targeting lung, ovarian, and pancreatic cancers, alongside the CoVepiT vaccine for COVID-19, OSE-172 and CLEC-1 for various cancers, a bispecific fusion protein platform, OSE-127 for ulcerative colitis and Sjogrens syndrome, FR104 for autoimmune diseases and transplantation, and OSE-230 for inflammation.
OSE Immunotherapeutics's top competitors include CareDx, ADMA Biologics and BioNTech.
OSE Immunotherapeutics offers Tedopi, OSE-279, Lusvertikimab, and Pegrizeprument.
Yes, OSE Immunotherapeutics is publicly traded on EURONEXT under the ticker symbol OSE.
OSE Immunotherapeutics has 1 investor. Key investors include Bpifrance.